Celularity Inc.

NASDAQ:CELU

Biotechnology

Healthcare
$1.83 +138.53%

+$1.22 today

Market cap
$52.97M
Beta
0.54
P/E (TTM)
-0.6
EPS (TTM)
-$3.58
52W Low $0.56High $4.00

Volume 0.00M

Average 0.13M

CELU Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Celularity Inc.NASDAQ: CELU

Financing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Financing cash flow growth accelerates

Q4 FY2025 financing cash flow of $11.22M rose 1644.9% year over year, ahead of the +178.3% change in trailing-twelve-month financing cash flow. Sequentially, it rose 222.6% from the prior quarter. Over 3 fiscal years it compounded at -46.2% a year.

Context

  • Financing cash flow amounted to 70.2% of revenue in FY2025, up 57.9 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1644.9% holds above the trailing-twelve-month pace of +178.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$11.22M+222.6% QoQ
Last fiscal yearDec 2025
$18.65M+178.3% YoY
LTMDec 2025
$18.65M+178.3% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1644.9%——
1 year+178.3%——
3-year CAGR-46.2%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
18.65M USD
Year-over-year change
+178.3%
4-year CAGR
-34.0%

Financing Cash Flow vs competitors

How CELU compares with its peers on the latest reported figures

  • CELU's LTM Dec 2025 financing cash flow of $18.65M is the largest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of +178.3% is the highest of 3, against a peer median of -80.4%.
  • Financing cash flow amounts to 70.2% of revenue for CELU, versus a peer median of 0.6%.
CELU Competitors Peer median
Financing Cash Flow for CELU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$18.65M +178.3%-46.2%70.2%
ANVSAnnovis Bio, Inc.LTM Mar 2026$18.52M -56.0%+19474.8%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$217K -104.7%—0.6%
PYPDPolyPid Ltd.LTM Dec 2025$0 ———
Peer median (excluding CELU) $0-80.4%+19474.8%0.6%

Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(100.12M)14.19M(196.3M)(57.89M)(91.72M)
Depreciation & Amortization8.82M9.44M11.48M7.92M7.3M
Deferred Income Tax00003K
Stock-Based Compensation40.01M15.86M15.02M11.57M10.38M
Change in Working Capital(5.71M)(15.45M)(6.77M)22.2M33.59M
Accounts Receivables(1.91M)(3.58M)(6.83M)(3.97M)7.55M
Inventory(6.42M)(16.89M)(865K)6.28M10.25M
Accounts Payables0009.24M3.13M
Other Working Capital2.62M5.02M919K10.65M12.67M
Other Non-Cash Items(53.1M)(161.91M)137.89M9.8M27.19M
Operating Cash Flow(110.1M)(137.88M)(38.69M)(6.4M)(13.25M)
Capital Expenditures(6.2M)(5.24M)(4.05M)(161K)0
Acquisitions (Net)000(1.5M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities300K002.18M0
Investing Cash Flow(5.9M)(5.24M)(4.05M)514K0
Debt Repayment039.2M11.31M7.1M(121K)
Common Stock Issued638K53.37M5.43M58K24.42M
Common Stock Repurchased00000
Dividends Paid0000(5.9M)
Other Financing Activities97.92M27.26M7.35M(459K)255K
Financing Cash Flow98.56M119.84M24.09M6.7M18.65M
Effect of Forex Changes00000
Net Change in Cash(17.44M)(23.27M)(18.64M)814K5.4M
Free Cash Flow(116.3M)(143.11M)(42.73M)(6.56M)(13.25M)

Celularity Inc.

NASDAQ:CELU

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.